-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25

Benzinga·09/09/2026 21:22:19
語音播報
Jefferies analyst Faisal Khurshid upgrades Summit Therapeutics (NASDAQ:SMMT) from Hold to Buy and raises the price target from $15 to $25.